bioTheranostics Receives Approval To Perform Breast Cancer Index Testing For Patients In State Of New York

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., a leading provider of genomic solutions for cancer patients, today announced that the New York State Department of Health has approved the use of its Breast Cancer IndexSM, a molecular test that determines risk of early and late recurrence and benefit from extended endocrine therapy in patients with early stage, estrogen receptor-positive breast cancer. With this approval, bioTheranostics can now perform Breast Cancer Index testing on tissue samples from patients in New York State.

Richard Ding, CEO of bioTheranostics, said, “We are pleased that the Breast Cancer Index has been approved by New York State, as its Clinical Laboratory Evaluation Program is one of the most rigorous in the nation. Its acceptance of validation data for the Breast Cancer Index is a milestone as we focus on commercializing the test and making it widely available to oncologists and breast cancer patients looking to make more-informed practice management and treatment decisions.”